- Morning Sickness
- Drugs in Pregnancy
- Alcohol, Nicotine, Substance Use
- Folic Acid
- Breastfeeding & Drugs
- Cancer in Pregnancy
- HIV and HIV Treatment
- Conditions in Pregnancy
- Infectious Diseases in Pregnancy
- Nutrition
- Occupational & Environmental Exposures
- Pharmacokinetics/ Drug Metabolism
- PregTox
- The ReproPsych Group
- CAS Newsletter
Our Helplines
1-877-327-4636 Alcohol and Substance
1-800-436-8477 Morning Sickness
1-888-246-5840 HIV and HIV Treatment
1-877-439-2744 Motherisk Helpline
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
St. John's,NL
2013 FACE meeting
Orlando, Florida
Fetal Alcohol Canadian Expertise (FACE) Satellite Meeting
.
-
Jul192012
-
Mar292012
-
Jul282011
-
Jan272011
- Read more in our News Archive
Current Studies at Motherisk
-
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
-
Pregnancy in Women with Multiple Sclerosis
-
Environmental Exposures and Children's Health
-
Alcohol Use during Pregnancy
-
Control of Hypertension in Pregnancy Study
-
Folic Acid Before and During Pregnancy
-
Lamisil in Pregnancy
-
Meridia in Pregnancy
-
Autoimmune Diseases in Pregnancy Project
The Cancer in Pregnancy Forum
Archived Questions and AnswersThis Forum has been the centre of an exceptional exchange of knowledge diagnosis, treatment, symptoms and other effects of cancer during pregnancy and lactation. All are welcome to review the Questions and Answers posted here, provided that they acknowledge and accept the important proviso and disclaimer below.
CCoPE
Date: 2002-08-26
Question:
My patient has been diagnosed recently with nasopharyngeal carcinoma and will start radiotherapy treatment soon. Unfortunately she is also pregnant now in the first trimester.Will the radiation therapy affect the fetus to warrant an abortion? We have had 3 patients with naso-pharingeal carcinoma that had a major resection (Commando operation?). Is surgical removal an option for this tumor?
Answer:
A distance of over 30 cm from the field edges to the uterus (in this case radiotherapy to the head and neck) should result in an exposure to the embryo-fetus of only 4 to 20 cGy (the acceptable dose is up to 10 cGy). Lead shielding over the uterus should be used to reduce the dose, and with this direct radiotherapy to the pharynx should not be a risk. A dosimetry of scatter to the pelvis (with shielding) should be performed as the radiation is planned. If the scatter to the pelvis is low there is no need for termination. The plans for radiation may be altered to minimize such scatter. More details on radiotherapy are provided in the Cancer in Pregnancy section of the Motherisk website.












![Validate my RSS feed [Valid RSS]](/images/rssValid.png)